Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study, Japan)
jRCT2080223287Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Solanezumab arm with Placebo arm (2 arms). Started Aug 2016; status: completed.
02
Drugs
solanezumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2080223287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223287.